Royalty Pharma (RPRX) EBIT Margin (2019 - 2026)

Royalty Pharma has reported EBIT Margin for 8 years, with the latest figure at 89.29% in Q1 2026.

• Quarterly EBIT Margin fell 472.0% year-over-year to 89.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 65.08% (down 1886.0% YoY) and the FY2025 annual result came in at 65.58%, up 848.0% from the prior year.
• EBIT Margin improved to 89.29% in Q1 2026 per RPRX's latest filing, from 62.44% in the prior quarter.
• Over five years, EBIT Margin peaked at 130.17% in Q3 2024 and troughed at 85.31% in Q4 2022.
• A 5-year average of 52.09% and a median of 60.9% in 2024 frame the typical range for EBIT Margin.
• The sharpest annual moves came in 2022 and 2023: EBIT Margin sank 11196 bps in 2022, then surged 18814 bps in 2023.
• Over 5 years, EBIT Margin stood at 85.31% in 2022, then jumped by 221 bps to 102.82% in 2023, then tumbled by 41 bps to 60.9% in 2024, then gained by 3 bps to 62.44% in 2025, then jumped by 43 bps to 89.29% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 89.29%, 62.44%, and 70.11% for Q1 2026, Q4 2025, and Q3 2025 respectively.